Gyre Therapeutics acquires Cullgen

Gyre Therapeutics agreed to acquire Cullgen. Reported deal value: $300M. Status: Pending. Sector: biopharmaceutical. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-03-02. Figures and status may change as filings and press coverage update.

Gyre Therapeutics , Inc. , an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced its agreement to acquire Cullgen Inc. , a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies, in an all-stock transaction valued at approximately $300 million